Globe Newswire

Saint Vincent e Grenadine, Caribbean, May 17, 2024 (GLOBE NEWSWIRE) -- In an ever-evolving investment landscape, AthenaDexFi emerges as a beacon of innovation, offering investors a diverse array of investment avenues tailored for success. Today, AthenaDexFi proudly announces the launch of its highly anticipated pre-sale for ATH Token, promising investors unparalleled profitability and peace of mind, along with an exclusive airdrop bonus.

AthenaDexFi, a... (continue reading...)

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company... (continue reading...)

SINGAPORE, May 17, 2024 (GLOBE NEWSWIRE) -- Primech Holdings Limited (Nasdaq: PMEC) ("Primech" or the "Company"), an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore, today announces that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 14, 2024 indicating that the Company is not currently in... (continue reading...)

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Nvni Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), the leading serial acquirer of private SaaS B2B companies in Latin America, announced that it received a notice of non-compliance (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its annual report for the fiscal year ended... (continue reading...)

NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 17,180 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and... (continue reading...)